XTAI
2465
Market cap252mUSD
Oct 08, Last price
85.70TWD
1D
-3.71%
1Q
-4.25%
Jan 2017
504.29%
IPO
60.78%
Name
Leadtek Research Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Leadtek Research Inc. engages in design, manufacturing, and trading of communication devices, computers, communications, telecommunications, and peripheral equipment in the United States, Hong Kong, South Korea, Taiwan, Mainland China, and internationally. It operates through two segments: Computer Product Department and Smart Healthcare Department. The company provides virtual desktop systems, including zero and thin client series products, management consoles, and remote workstation cards; graphics cards; professional graphics; AI and high performance computing; AI inference devices; GPU docker management systems and RTX AI software packs; and workstations and servers. It also offers health watches, wearable ECG recorders, fingertip and wearable pulse oximeters, stethoscope recording devices, portable ECG Recorders, biomolecular scanners, ring, deep relief patches, and facial repairing essence; and amor H3 Plus Patch, a non-invasive ECG and audio signal recorder. In addition, the company engages in the provision of after-sales services; software agency, brokerage, trading, and operations; research and development, agency, production, and sales of medical devices and health food; and installation of computer equipment and data processing. The company was founded in 1986 and is headquartered in New Taipei City, Taiwan.
Key people
Kunshan Lu
Chairman of the Board · since 2025
Jindian Yang
Chief Technology Officer · since 2014
Chuanjie Liang
General Manager · since 2025
Dongzhen Gu
Senior Deputy General Manager-Finance, Head of Finance · since 2013
Shen Zhang
Deputy General Manager-Finance Division · since 2025
Shiwei Zhou
Deputy General Manager · since 2005
Jiahong Wang
Chief Information Security Officer · since 2023
Jianfa Liang
Director · since 2024
Jianda Liang
Director · since 2024
Han-tang Chang
Independent Director · since 2025
De-ming Chen
Independent Director · since 2025
Independent Director · since 2017
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||